These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35485994)

  • 1. Fecal luminal factors from patients with irritable bowel syndrome induce distinct gene expression of colonoids.
    Iribarren C; Nordlander S; Sundin J; Isaksson S; Savolainen O; Törnblom H; Magnusson MK; Simrén M; Öhman L
    Neurogastroenterol Motil; 2022 Oct; 34(10):e14390. PubMed ID: 35485994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal Luminal Factors from Patients with Gastrointestinal Diseases Alter Gene Expression Profiles in Caco-2 Cells and Colonoids.
    Holst LM; Iribarren C; Sapnara M; Savolainen O; Törnblom H; Wettergren Y; Strid H; Simrén M; Magnusson MK; Öhman L
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids.
    Han X; Lee A; Huang S; Gao J; Spence JR; Owyang C
    Gut Microbes; 2019; 10(1):59-76. PubMed ID: 30040527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure of Colon-Derived Epithelial Monolayers to Fecal Luminal Factors from Patients with Colon Cancer and Ulcerative Colitis Results in Distinct Gene Expression Patterns.
    Magnusson MK; Bas Forsberg A; Verveda A; Sapnara M; Lorent J; Savolainen O; Wettergren Y; Strid H; Simrén M; Öhman L
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome.
    Ahluwalia B; Iribarren C; Magnusson MK; Sundin J; Clevers E; Savolainen O; Ross AB; Törnblom H; Simrén M; Öhman L
    Cells; 2021 Jun; 10(6):. PubMed ID: 34200772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multispecies probiotic protects gut barrier function in experimental models.
    Nébot-Vivinus M; Harkat C; Bzioueche H; Cartier C; Plichon-Dainese R; Moussa L; Eutamene H; Pishvaie D; Holowacz S; Seyrig C; Piche T; Theodorou V
    World J Gastroenterol; 2014 Jun; 20(22):6832-43. PubMed ID: 24944474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome.
    Duboc H; Rainteau D; Rajca S; Humbert L; Farabos D; Maubert M; Grondin V; Jouet P; Bouhassira D; Seksik P; Sokol H; Coffin B; Sabaté JM
    Neurogastroenterol Motil; 2012 Jun; 24(6):513-20, e246-7. PubMed ID: 22356587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion.
    Camilleri M; Carlson P; Acosta A; Busciglio I
    Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G10-20. PubMed ID: 25930081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interplay between bile acid metabolism and microbiota in irritable bowel syndrome.
    Dior M; Delagrèverie H; Duboc H; Jouet P; Coffin B; Brot L; Humbert L; Trugnan G; Seksik P; Sokol H; Rainteau D; Sabate JM
    Neurogastroenterol Motil; 2016 Sep; 28(9):1330-40. PubMed ID: 27060367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome.
    Carroll IM; Ringel-Kulka T; Keku TO; Chang YH; Packey CD; Sartor RB; Ringel Y
    Am J Physiol Gastrointest Liver Physiol; 2011 Nov; 301(5):G799-807. PubMed ID: 21737778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.
    Maharshak N; Ringel Y; Katibian D; Lundqvist A; Sartor RB; Carroll IM; Ringel-Kulka T
    Dig Dis Sci; 2018 Jul; 63(7):1890-1899. PubMed ID: 29777439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered intestinal antibacterial gene expression response profile in irritable bowel syndrome is linked to bacterial composition and immune activation.
    Bennet SMP; Sundin J; Magnusson MK; Strid H; Tap J; Derrien M; Le Nevé B; Doré J; Törnblom H; Simrén M; Öhman L
    Neurogastroenterol Motil; 2018 Dec; 30(12):e13468. PubMed ID: 30230134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of fecal metabolic profiles in patients with irritable bowel syndrome with predominant diarrhea investigated using
    Lee JS; Kim SY; Chun YS; Chun YJ; Shin SY; Choi CH; Choi HK
    Neurogastroenterol Motil; 2020 Jun; 32(6):e13830. PubMed ID: 32125749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype.
    Belmonte L; Beutheu Youmba S; Bertiaux-Vandaële N; Antonietti M; Lecleire S; Zalar A; Gourcerol G; Leroi AM; Déchelotte P; Coëffier M; Ducrotté P
    PLoS One; 2012; 7(8):e42777. PubMed ID: 23028414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar Fecal Microbiota Signatures in Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Patients With Depression.
    Liu Y; Zhang L; Wang X; Wang Z; Zhang J; Jiang R; Wang X; Wang K; Liu Z; Xia Z; Xu Z; Nie Y; Lv X; Wu X; Zhu H; Duan L
    Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1602-1611.e5. PubMed ID: 27266978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal chromogranins and secretogranins are linked to the fecal and mucosal intestinal bacterial composition of IBS patients and healthy subjects.
    Sundin J; Stridsberg M; Tap J; Derrien M; Le Nevé B; Doré J; Törnblom H; Simrén M; Öhman L
    Sci Rep; 2018 Nov; 8(1):16821. PubMed ID: 30429499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea.
    Camilleri M; Busciglio I; Acosta A; Shin A; Carlson P; Burton D; Ryks M; Rhoten D; Lamsam J; Lueke A; Donato LJ; Zinsmeister AR
    Am J Gastroenterol; 2014 Oct; 109(10):1621-30. PubMed ID: 25070056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the mechanism of Xingpi Capsule in diarrhea predominant-irritable bowel syndrome treatment based on multiomics technology.
    Qian W; Li W; Chen X; Cui L; Liu X; Yao J; Wang X; Liu Y; Li C; Wang Y; Wang W
    Phytomedicine; 2023 Mar; 111():154653. PubMed ID: 36641976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
    Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
    Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Expression of Colonic Mucosal Melatonin in Patients with Irritable Bowel Syndrome Correlated with Gut Dysbiosis.
    Wang B; Zhu S; Liu Z; Wei H; Zhang L; He M; Pei F; Zhang J; Sun Q; Duan L
    Genomics Proteomics Bioinformatics; 2020 Dec; 18(6):708-720. PubMed ID: 33607299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.